Bayer today significantly tightened its limits on 340B pricing when hospitals contract with pharmacies to dispense drugs to patients.
Drug manufacturer Bayer this morning significantly tightened its limits on 340B pricing when hospital covered entities contract with pharmacies to dispense drugs to patients. Grantee entities remain exempt from Bayer’s restrictions.
U.S. Reps. Dusty Johnson (R-S.D.) and Abigail Spanberger (D-Va.) reintroduced legislation to protect 340B covered entities, contract pharmacies, and individuals with private insurance from discrimination by pharmacy benefit managers and insurance companies.
A Virginia Democrat and South Dakota Republican this afternoon reintroduced bipartisan legislation in the U.S. House to protect 340B covered entities and contract pharmacies from discrimination by insurers and pharmacy benefit managers.
“There’s been a lot of criticism of the 340B program lately and I’m concerned about the conversation on 340B happening today,” Rep. Doris Matsui (D-Calif.) said during a House Energy & Commerce health subcommittee hearing today.
The 340B program was discussed at length today during a U.S. House subcommittee hearing on price transparency and consolidation in health care, with three Republicans questioning whether hospitals are abusing the program and two Democrats and a Republican
Lt. Cmdr. Emeka Egwim (left), Director of HRSA's Office of Pharmacy Affairs, spoke this morning on 340B Day at NACHC's annual Policy & Issues Forum in Washington, D.C.
A large HIV/AIDS health care group, a Democratic 340B provider ally in Congress, and three national hospital groups lambasted community health centers and drug makers’ historic announcement yesterday that they are working together to remake the 340B program.